At the Venture Awards Russia 2015 ceremony, December 5, Russia’s first VC award went to RBV Capital in the New Player of the Year nomination.
RetroSense Therapeutics Raises $6 million in an Over-Subscribed Series B Financing to Advance Clinical Development of Lead Product RST‐001 for Retinitis Pigmentosa
Patient recruitment underway for Phase I/II clinical study RetroSense Therapeutics, a privately‐held, clinical-stage biopharmaceutical company, today announced that it has secured $6 million in a Series B financing to further investigate the use of gene therapy and optogenetics to restore vision.
The managing company of RBV Capital has an open position for an investment analyst/manager. Background/education in medicine, biotech or life sciences, investment experience in pharma/healthcare, work experience in pharma companies or other relevant experience very welcome.
LONDON, United Kingdom, April 27, 2015 – Image Analysis Limited, a privately-held digital health software and services provider of medical imaging analysis in clinical trials and daily clinical practice, has completed a $5.2m venture financing with Danish Research Foundation (DRF) and RBV Capital.
R-Pharm jointly with RVC announced the establishment of a venture capital fund in the sphere of medical technology, RusBio Ventures. The amount of finance under management by the fund at the first closing will be RUB 2.07 bln.